Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services | News
Search Refinements

Contract Services News

View news from other Pharmaceutical sectors:
91-105 of 2369 results
Impax Laboratories to buy generic products from Teva and Allergan for $586m
By PBR Staff Writer
Impax Laboratories has agreed to acquire a portfolio of generic drugs from Teva Pharmaceutical Industries and Allergan for about $586m.
Contract Research & Services > Contract Services > News
Cipher Pharmaceuticals out-licenses rights to ASF-1096 for anorectal disorders
Cipher Pharmaceuticals announced that Edesa Biotech has licensed the rights to ASF-1096 (R-salbutamol) for use in anorectal disorders.
Contract Research & Services > Contract Services > News
Sagent Pharmaceuticals to buy product portfolio from Teva Pharmaceutical Industries
Sagent Pharmaceuticals has entered into a definitive agreement with Teva Pharmaceutical Industries and Actavis to acquire a portfolio of five Abbreviated New Drug Applications (ANDAs) in the U.S. for $40m.
Contract Research & Services > Contract Services > News
Clinigen signs global access deal with Galen for chemotherapy drug DaunoXome
By PBR Staff Writer
Clinigen Group has signed a supply agreement with pharmaceutical firm Galen for chemotherapy drug DaunoXome.
Contract Research & Services > Contract Services > News
Faron Pharmaceuticals licenses Traumakine Korean rights to Pharmbio Korea
Faron Pharmaceuticals has entered into a licensing agreement with Pharmbio Korea for the development and commercialisation of Traumakine in Korea.
Contract Research & Services > Contract Services > News
Aspen to buy rights to AstraZeneca’s global anaesthetics portfolio outside US
By PBR Staff Writer
Aspen Global Incorporated (AGI) has agreed to acquire AstraZeneca’s worldwide anaesthetics portfolio, excluding the US, for about $520m.
Contract Research & Services > Contract Services > News
CRISPR gains license to Anagenesis’ P2MCs technology for cell therapy for muscle diseases
CRISPR Therapeutics and Anagenesis Biotechnologies announced a strategic in-licensing and collaboration agreement, which grants CRISPR Therapeutics exclusive worldwide license to Anagenesis’ Paraxial Mesoderm Multipotent Cells (P2MCs) technology for cell therapy for all human muscle diseases.
Contract Research & Services > Contract Services > News
ViiV Healthcare signs public tender deal with Botswana Ministry of Health for dolutegravir
ViiV Healthcare, a global specialist HIV company majority owned by GSK, with Pfizer and Shionogi Limited as shareholders, confirmed a public tender agreement with the Ministry of Health in Botswana to support the implementation of a new national ‘Treat All’ programme which aims to ensure people living with HIV in the country get tested and receive treatment.
Contract Research & Services > Contract Services > News
ARIAD completes sale of European operations and out-license of European rights to Iclusig
ARIAD Pharmaceuticals has completed the sale of its European operations to Incyte and entered into the previously announced license agreement for Incyte to exclusively license Iclusig (ponatinib) in Europe and other select countries.
Contract Research & Services > Contract Services > News
AstraZeneca agrees to sell Zurampic's European & Latin American rights to Grunenthal
By PBR Staff Writer
AstraZeneca has agreed to license exclusive rights to the gout-associated hyperuricemia drug Zurampic (lesinurad) in Europe and Latin America to Grünenthal.
Contract Research & Services > Contract Services > News
Lipidor, Cadila sign deal on joint commercialization of topical Psoriasis product
Lipidor and Cadila Pharmaceuticals have entered into a collaboration agreement on the commercialization of a sprayable anti-psoriatic product consisting of the generic Vitamin D analogue, Calcipotriol, formulated with Lipidor´s patented lipid-based drug delivery technology, AKVANO.
Contract Research & Services > Contract Services > News
Genmab to receive $30m milestone payment from Janssen in Darzalex collaboration
By PBR Staff Writer
Danish biotechnology firm Genmab will receive $30m payment from Janssen Biotech under Darzalex (daratumumab) collaboration.
Contract Research & Services > Contract Services > News
TG Therapeutics enters into global collaboration to develop Jubilant's novel BET inhibitor program
TG Therapeutics unveiled that as part of a broader agreement with Indian biotechnology firm Jubilant Biosys, it has entered into a sub-license agreement with Checkpoint Therapeutics to develop and commercialize Jubilant's novel BET inhibitor program in the field of hematological malignancies.
Contract Research & Services > Contract Services > News
PDL BioPharma commits to equity investment in Noden Pharma
PDL BioPharma has committed to an equity investment in Noden Pharma DAC, a new privately held company that has executed a purchase agreement with Novartis to acquire exclusive worldwide rights to manufacture, market, and sell the branded prescription medicine product sold under the name Tekturna and Tekturna HCT in the US and Rasilez and Rasilez HCT in the rest of the world.
Contract Research & Services > Contract Services > News
BioPharma Services wins $20m contract from FDA's Center for Drug Evaluation and Research
BioPharma Services USA, Inc. (BioPharma) has been awarded a 5-year, $20m contract with the Center for Drug Evaluation and Research (CDER), a division of the US Food and Drug Administration (FDA).
Contract Research & Services > Contract Services > News
91-105 of 2369 results